Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis

Bissonnette Robert; Pariser David M.; Wasel Norman R.; Goncalves Joana; Day Robert M.; Chen Rongdean; Sebastian Michael

首页> 外文期刊>Journal of the American Academy of Dermatology >Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis

【24h】

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis

机译：口服磷酸二酯酶4抑制剂Apremilast在治疗掌足型牛皮癣中的应用：II期PSOR-005和III期疗效和安全性试验的合并分析结果，评估了Apremilast对银屑病（ESTEEM）在中度患者中的临床试验的效果重度牛皮癣

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Difficult-to-treat palmoplantar psoriasis has a disproportionately negative impact on quality of life.

机译：背景：难以治疗的掌plant型银屑病对生活质量产生不成比例的负面影响。

著录项

来源
《Journal of the American Academy of Dermatology》 |2016年第1期|共7页
作者
Bissonnette Robert; Pariser David M.; Wasel Norman R.; Goncalves Joana; Day Robert M.; Chen Rongdean; Sebastian Michael;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类皮肤病学与性病学;
关键词
apremilast; difficult to treat; ESTEEM; moderate to severe; palmoplantar psoriasis; palms; PSOR-005; soles;

机译：前者;难治性;ESTEEM;中度至重度;足plant牛皮癣;手掌;PSOR-005;鞋底;

相似文献

外文文献
中文文献

1. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis [J] . Bissonnette Robert, Pariser David M., Wasel Norman R., Journal of the American Academy of Dermatology . 2016,第1期

机译：口服磷酸二酯酶4抑制剂Apremilast在治疗掌足型牛皮癣中的应用：II期PSOR-005和III期疗效和安全性试验的合并分析结果，评估了Apremilast对银屑病（ESTEEM）在中度患者中的临床试验的效果重度牛皮癣
2. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) [J] . Papp Kim, Reich Kristian, Leonardi Craig L., Journal of the American Academy of Dermatology . 2015,第1期

机译：口服磷酸二酯酶4（PDE4）抑制剂Apremilast在中度至重度斑块状牛皮癣患者中的应用：一项III期随机对照试验的结果（疗效和安全性试验，评估Apremilast对牛皮癣的影响[ESTEEM] 1）
3. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2) [J] . Paul C., Cather J., Gooderham M., British Journal of Dermatology . 2015,第6期

机译：口服磷酸二酯酶4抑制剂apremilast对52周以上中度至重度斑块状牛皮癣患者的疗效和安全性：III期随机对照试验（ESTEEM 2）
4. Combining Dosimetry Toxicity: Analysis of two UK Phase III Clinical trials [C] . Sarah L Gulliford ICCR . 2014

机译：结合剂量测定和毒性：两个英国第三期临床试验分析
5. Recruitment, retention and compliance in randomized, phase III clinical trials involving obese patients diagnosed with type 2 Diabetes Mellitus with respect to weight loss practicum report. [D] . Mithani, Moez S. 2012

机译：涉及诊断为2型糖尿病的肥胖患者的有关减肥实践的随机III期临床试验中的招募，保留和依从性报告。
6. Apremilast an oral phosphodiesterase 4 inhibitor improves patient‐reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized controlled trials [O] . D. Thaçi, A. Kimball, P. Foley, -1

机译：口服磷酸二酯酶4抑制剂Apremilast改善了患者报告的中重度牛皮癣的治疗结果：两项III期随机对照试验的结果
7. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis [O] . Bissonnette Robert, Pariser David M., Wasel Norman R., 2016

机译：口服磷酸二酯酶-4抑制剂Apremilast在治疗掌足型牛皮癣中的应用：II期PSOR-005和III期有效性和安全性试验的合并分析结果，评估了Apremilast对银屑病（ESTEEM）在中度患者中的临床试验的效果重度牛皮癣

摘要

著录项

相似文献

相关主题

期刊订阅